Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962120 | 0.85 | MMP2 (0.40) | CTSKFFAR1FFAR4CES1DAGLA | |
| SCHEMBL29593228 | 0.83 | SOS2 (0.39) | CES1 | |
| SCHEMBL24031001 | 0.83 | SOS2 (0.39) | CES1 | |
| SCHEMBL6783633 | 0.82 | KEAP1 (0.52) | FFAR1KEAP1 | |
| SCHEMBL2952813 | 0.80 | MMP2 (0.41) | CTSKFFAR1FFAR4CES1DAGLA | |
| SCHEMBL2956236 | 0.80 | MAPK1 (0.40) | CES1DAGLA | |
| SCHEMBL21199960 | 0.79 | HSD11B1 (0.44) | CTSK | |
| SCHEMBL14732983 | 0.78 | KCNH2 (0.44) | CTSKCES1DAGLA | |
| SCHEMBL2962806 | 0.78 | ALDH1A1 (0.38) | CTSKCES1DAGLA | |
| SCHEMBL17115651 | 0.78 | NPSR1 (0.40) | CTSKCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | CTSK 2868/4885FFAR1 2851/4885FFAR4 3518/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | CTSK 2868/4885FFAR1 2851/4885FFAR4 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.